enGene’s (ENGN) Market Perform Rating Reaffirmed at Citizens Jmp

enGene (NASDAQ:ENGN)‘s stock had its “market perform” rating reaffirmed by equities researchers at Citizens Jmp in a report released on Wednesday, Benzinga reports.

Several other equities research analysts have also recently issued reports on ENGN. HC Wainwright restated a “buy” rating and issued a $4.00 target price on shares of enGene in a report on Tuesday. Citigroup reissued a “market perform” rating on shares of enGene in a report on Wednesday. Morgan Stanley downgraded enGene from an “equal weight” rating to an “underweight” rating and set a $3.00 price target on the stock. in a research note on Thursday, June 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of enGene in a report on Wednesday, August 12th. Finally, Wall Street Zen upgraded enGene from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th. Four investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $11.05.

enGene Price Performance

Shares of NASDAQ:ENGN opened at $1.92 on Wednesday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 12.57 and a current ratio of 12.57. The firm has a market cap of $128.62 million, a price-to-earnings ratio of -0.88 and a beta of -0.28. The business has a 50-day simple moving average of $1.82 and a two-hundred day simple moving average of $4.05. enGene has a fifty-two week low of $1.40 and a fifty-two week high of $12.25.

enGene (NASDAQ:ENGN) last announced its quarterly earnings results on Tuesday, September 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.04). On average, analysts expect that enGene will post -1.75 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. SR One Capital Management LP bought a new stake in shares of enGene during the 2nd quarter valued at $1,293,607. Siren L.L.C. boosted its holdings in enGene by 57.5% in the 1st quarter. Siren L.L.C. now owns 5,253,159 shares of the company’s stock worth $35,774,000 after buying an additional 1,916,895 shares during the period. Perceptive Advisors LLC increased its stake in enGene by 179.8% in the 4th quarter. Perceptive Advisors LLC now owns 5,869,076 shares of the company’s stock worth $52,998,000 after buying an additional 3,771,840 shares in the last quarter. Cormorant Asset Management LP increased its stake in enGene by 72.1% in the 4th quarter. Cormorant Asset Management LP now owns 4,000,000 shares of the company’s stock worth $36,120,000 after buying an additional 1,676,405 shares in the last quarter. Finally, Eventide Asset Management LLC bought a new stake in enGene during the fourth quarter valued at about $8,578,000. 64.16% of the stock is owned by hedge funds and other institutional investors.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.